Trial · NCT02307682
Results by group1,112
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 1,112
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Best Corrected Visual Acuity (BCVA) (Letters Read) at Week 48 - Study Eye | Brolucizumab 3 mg | 5.9 | Standard Deviation 13.49 | letters | |
| Change From Baseline in Best Corrected Visual Acuity (BCVA) (Letters Read) at Week 48 - Study Eye | Brolucizumab 6 mg | 6.4 | Standard Deviation 14.40 | letters | |
| Change From Baseline in Best Corrected Visual Acuity (BCVA) (Letters Read) at Week 48 - Study Eye | Aflibercept 2 mg | 7.0 | Standard Deviation 13.16 | letters | |
| Average Change From Baseline in BCVA (Letters Read) Over the Period Week 36 Through Week 48 - Study Eye | Brolucizumab 3 mg | 6.0 | Standard Deviation 13.37 | letters | |
| Average Change From Baseline in BCVA (Letters Read) Over the Period Week 36 Through Week 48 - Study Eye | Brolucizumab 6 mg | 6.5 | Standard Deviation 13.85 | letters | |
| Average Change From Baseline in BCVA (Letters Read) Over the Period Week 36 Through Week 48 - Study Eye | Aflibercept 2 mg | 6.9 | Standard Deviation 12.61 | letters | |
| Proportion of Subjects With Positive q12 (Every 12 Weeks) Treatment Status at Week 48 | Brolucizumab 3 mg | 0.4939 | 95% Confidence Interval 0.4393 to 0.5461 | proportion of subjects | |
| Proportion of Subjects With Positive q12 (Every 12 Weeks) Treatment Status at Week 48 | Brolucizumab 6 mg | 0.5563 | 95% Confidence Interval 0.5016 to 0.6075 | proportion of subjects | |
| Proportion of Subjects With Positive q12 Treatment Status at Week 48 Within the Subjects With no q8 (Every 8 Weeks) Treatment Need During the First q12 Cycle (Week 16, Week 20) | Brolucizumab 3 mg | 0.8085 | 95% Confidence Interval 0.7454 to 0.8574 | proportion of subjects | |
| Proportion of Subjects With Positive q12 Treatment Status at Week 48 Within the Subjects With no q8 (Every 8 Weeks) Treatment Need During the First q12 Cycle (Week 16, Week 20) | Brolucizumab 6 mg | 0.8539 | 95% Confidence Interval 0.7987 to 0.8950 | proportion of subjects | |
| Proportion of Subjects With Positive q12 Treatment Status up to Week 96 | Brolucizumab 3 mg | 0.3973 | 95% Confidence Interval 0.3427 to 0.4514 | proportion of subjects | |
| Proportion of Subjects With Positive q12 Treatment Status up to Week 96 | Brolucizumab 6 mg | 0.4537 | 95% Confidence Interval 0.3984 to 0.5072 | proportion of subjects | |
| Proportion of Subjects With Positive q12 Treatment Status at Week 96 Within the Subjects With no q8 Treatment Need During the Initial q12 Cycle (Week 16, Week 20) | Brolucizumab 3 mg | 0.6504 | 95% Confidence Interval 0.5749 to 0.7159 | proportion of subjects | |
| Proportion of Subjects With Positive q12 Treatment Status at Week 96 Within the Subjects With no q8 Treatment Need During the Initial q12 Cycle (Week 16, Week 20) | Brolucizumab 6 mg | 0.6963 | 95% Confidence Interval 0.6270 to 0.7554 | proportion of subjects | |
| Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye | Brolucizumab 3 mg | Change from baseline at Week 4 | 3.7 | Standard Deviation 8.36 | letters |
| Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye | Brolucizumab 6 mg | Change from baseline at Week 4 | 3.8 | Standard Deviation 9.77 | letters |
| Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye | Aflibercept 2 mg | Change from baseline at Week 4 | 4.2 | Standard Deviation 7.93 | letters |
| Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye | Brolucizumab 3 mg | Change from baseline at Week 8 | 5.7 | Standard Deviation 8.83 | letters |
| Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye | Brolucizumab 6 mg | Change from baseline at Week 8 | 5.5 | Standard Deviation 10.71 | letters |
| Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye | Aflibercept 2 mg | Change from baseline at Week 8 | 6.1 | Standard Deviation 9.48 | letters |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02307682/results